IJCRAR is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCRAR Articles.

INDEXED IN INDEX COPERNICUS - ICI Journals Master List 2016 - IJCRAR--ICV 2016: 81.15 For more details click here

Abstract                 Volume:4  Issue-12  Year-2016          Original Research Articles

Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcret@gmail.com

Determine Suitability of Isoxyl, A Mycolic Acid Inhibitor for Intermittent Chemotherapy of Tuberculosis
Shashikant Vaidya1*, Shreyasi Muley2, Mohan Kulkarni3, Geeta Koppikar4 and Abhay Chowdhary5
1Clinical Pathology department, Haffkine Institute, Mumbai, India
2Haffkine Bio-pharmaceutical Corporation Ltd. Mumbai, India
3T.N. Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India4Breach Candy hospital trust, Mumbai, India
5Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India
*Corresponding author

Intermittent chemotherapy is attractive. If drugs can be given less frequently than once a day, fully supervised treatment is much easier. In managing patients with tuberculosis (TB), administration of drugs at intermittent intervals would reduce cost and possibly toxicity of drugs, as well as enhance adherence through greater feasibility of directly observed therapy. There is an urgent need to develop new effective antitubercular compounds, compounds that increase the permeability of the mycobacterial cell wall by inhibiting the synthesis of cell wall components and enhance the activity of conventional drugs as a result of increased penetration of these latter agents to susceptible internal targets. As drug development is a long and expensive process, it becomes predominant to reexamine drugs that were formerly deemed effective against TB and increase the permeability of the Mycobacterial cell wall. One such drug is Isoxyl (ISO). ISO is an old drug, used for the clinical treatment of TB in 1960’s. Hence there was a thought to recheck its efficacy against Mycobacterium tuberculosis strains as it is an old drug which have proven its efficacy. Present study was conducted with the objective, to determine suitability of ISO for intermittent chemotherapy of TB.In vitro Pulsed exposure study of ISO against Test culture and Standard strain of M. tuberculosis H37 Rv after growth of test organisms in log phase was carried out. Viable counts were carried out before addition of drug, immediately after washing and at intervals thereafter.Sensitivity tests were set up on sterile LJM slants. The effect of exposure was estimated by noting the delay before the organisms began to grow. Pulsed exposure study of ISO in infected macrophages was also done. The rate of growth in the cultures after exposure to ISO was similar to the usual growth rate. ISO was not bactericidal during exposure and growth began immediately after the drug was removed by washing. There was significant difference, after applying un-paired t-test ,in the bacterial count observed by exposure in INH 1 mcg/ml (24 hrs exposure) and ISO 10 mcg/ ml (24 hrs exposure) and 10 mcg/ml (96 hrs exposure) concentrations. Same observations made in pulse exposure study of ISO in macrophage cell line.  Summarizing, the assessment of suitability for intermittent chemotherapy, it seems likely that ISO would be least satisfactory. Some caution must be expressed about extrapolating the results of in vitro experiments and to the treatment of human TB. There is no adequate substitute for clinical studies of intermittent treatment of pulmonary tuberculosis with ISO.

Keywords: Isoxyl,A Mycolic Acid,Chemotherapy of Tuberculosis.
Download this article as Download

How to cite this article:

Shashikant Vaidya, Shreyasi Muley, Mohan Kulkarni, Geeta Koppikar, Abhay Chowdhary. 2016. To Determine Suitability of Isoxyl, A Mycolic Acid Inhibitor for Intermittent Chemotherapy of Tuberculosis.Int.J.Curr.Res.Aca.Rev. 4(12): 85-92
doi: http://dx.doi.org/10.20546/ijcrar.2016.412.008